Kevin Dalgaard is a Principal at Lundbeckfonden BioCapital, the venture capital team of the Danish enterprise foundation, Lundbeckfonden, where the focus is to invest in and build companies within life sciences. Prior to joining the foundation Kevin worked at Novo Nordisk and Boehringer Ingelheim for several years in various positions within R&D, Global Marketing, and Business Development providing him a great insight and understanding of the whole value chain in the pharma industry. 

Kevin holds an MSc in Biochemistry from the University of Copenhagen, and a Ph.D. from Max Planck Institute. Kevin has several high-impact publications including a first-author publication in ‘Cell’.